{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"data_sharing_plan":["IPD Sharing (as of June 2022): No"],"condition":["Non-Small Cell Lung Cancer","Endometrial cancer","HER2 Positive Solid Tumors","Gastrointestinal Cancer","Gastric Cancer","Colorectal Cancer","Head and neck cancer","Breast Cancer","Neoplasms"],"disease":["Endometrial Cancer","Gastrointestinal Cancer","Gastric Cancer","Colorectal Cancer","Non-small Cell Lung Cancer","Her2 Positive Solid Tumors","Head And Neck Cancer","Breast Cancer","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2344768"],"location":["South Korea","United States","Australia"],"study_start_month":["7"],"keyword":["Stomach Cancer","Urothelial cancer","TLR8 agonist","Anti-PD-1 mAb","Biliary tract cancer","Triple Negative Breast Cancer","Monoclonal antibody","Antibody drug conjugate","Pembrolizumab","Gastroesophageal junction","Immunotherapy","ERBB2","Cemiplimab","TLR8","HER2"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors","description":"A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies","dates":{"creation":"2020-07-15"},"accession":"2344768","cross_references":{"ClinicalTrials___gov":["NCT04460456"]}}